COMMUNIQUÉS West-GlobeNewswire

Nu-Tek BioSciences Earns EcoVadis Bronze Rating for Third Consecutive Year, Strengthening Sustainable Biopharmaceutical Supplier Status
11/08/2026
EcoVadis recognition reinforces Nu-Tek's sustained investment in the sustainable manufacturing of animal-origin-free cell culture media nutrients and fermentation ingredients. MINNETONKA, Minn., Aug. 11, 2026 (GLOBE [...]
Nu-Tek BioSciences obtient la Médaille de bronze décernée par EcoVadis pour la troisième année consécutive, consolidant ainsi son statut de fournisseur biopharmaceutique respectueux de l’environnement
11/08/2026
Cette distinction d’EcoVadis vient renforcer l’engagement continu de Nu-Tek en faveur de la fabrication durable de nutriments pour milieux de culture cellulaire et d’ingrédients de fermentation sans composants d’origine [...]
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
11/08/2026
– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic [...]
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma
11/08/2026
TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and [...]
Frishantic Introduces New Magnesium Complex for Women, Combining Seven Magnesium Forms with L-Theanine and Vitamin B6
11/08/2026
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Frishantic , a wellness brand focused on practical daily nutrition solutions, has introduced its new Magnesium Complex for Women , a multi-ingredient supplement designed to [...]
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11/08/2026
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric [...]
Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
11/08/2026
Files Definitive Proxy Statement and Mails Letter to Stockholders Urges Stockholders to Vote "FOR" All Six Anavex Director Nominees on the WHITE Proxy Card Underscores PVG’s Lack of Clear Plan and Inexperienced Slate of [...]
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
11/08/2026
Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease On option exercise, Sentynl will have the right to commercialize the product in the [...]
NovelMed Advances Its Ocular Program, Highlighting the Potential of a Single Therapy Across Multiple Retinal Diseases
11/08/2026
--- A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial Precedent for One Molecule, Two Diseases : Biogen’s $5.6 billion acquisition of [...]
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
11/08/2026
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high- [...]
Noah Medical Announces Galaxy™ II, the Next Dimension in Robotic-Assisted Bronchoscopy
11/08/2026
New functionality gives physicians the freedom to choose the right imaging for every case and a more responsive drive experience without adding capital, complexity, or radiation SAN JOSE, Calif., Aug. 11, 2026 (GLOBE [...]
Gibson Oncology Announces First Patient Completes Initial Treatment Cycle in Phase II Trial of LMP744 for Recurrent Glioblastoma
11/08/2026
Novel Blood-Brain-Barrier-Penetrant Agent Being Evaluated as a Single Therapy in a Trial Conducted by the National Institute of Neurological Disorders and Stroke (NINDS) MIAMI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gibson [...]
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08/2026
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 [...]
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
11/08/2026
Two chrono-nutrition formulations — a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to [...]
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
11/08/2026
MALVERN, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient [...]
Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States
11/08/2026
TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting cardiac surgery- [...]
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
11/08/2026
President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board of Directors [...]
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
11/08/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured equity [...]
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
11/08/2026
Selected 0.60 mg/m 2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following [...]

Pages